Oric Pharmaceuticals, Inc.
ORICNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$143.0M | −$142.9M | −$110.8M | −$91.8M | −$78.9M | −$74.2M |
| Net income | −$129.5M | −$127.8M | −$100.7M | −$89.1M | −$78.7M | −$73.7M |
| Total assets | $408.9M | $274.1M | $252.0M | $247.2M | $298.6M | $299.0M |
| Total liabilities | $24.5M | $31.0M | $27.9M | $24.8M | $25.7M | $9.2M |
| Equity | $384.4M | $243.1M | $224.1M | $222.4M | $273.0M | $289.8M |
| EPS (diluted) | $-1.47 | $-1.83 | $-1.96 | $-2.25 | $-2.07 | — |
| Shares out. | 71.0M | 67.4M | 45.1M | 39.4M | 36.7M | 36.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −33.7%
- Return on assets
- −31.7%
- Return on capital (ROCE)
- −36.8%
- Liabilities / assets
- 6.0%
- Debt / equity
- 0.06×
- Book value / share
- $5.41
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 12.88safe
- Accruals / assets
- −4.5%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2025-12Study of ORIC-944 in Patients With Metastatic Prostate Cancer
- Phase 1/2Recruitingreadout ~2026-09Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
- Phase 1Recruitingreadout ~2026-12ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Venrock Healthcare Capital Partners Iii, L.P.Passive (13G)May 15, 2026
- Point72 Asset Management, L.P.Passive (13G)May 15, 2026
- Viking Global Investors LpPassive (13G)May 15, 2026
- Price T Rowe Associates Inc /Md/Passive (13G)May 15, 2026
- Pfizer IncPassive (13G)May 12, 2026
- Blackrock, Inc.Passive (13G)Jan 21, 2026
- Column Group Ii, LpPassive (13G)Nov 17, 2025
- Alkeon Capital Management LlcPassive (13G)Nov 13, 2025
- Nextech Crossover I Gp S.A R.L.Passive (13G)Aug 14, 2025
- Sr One Capital Management, LlcActivist (13D)Aug 14, 2025
- Ecor1 Capital, LlcPassive (13G)Aug 5, 2025
- Frazier Life Sciences Public Fund, L.P.Passive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Piscitelli DominicOfficer — Chief Financial Officer | Feb 24, 2026 | Option exercise | 52,000 | $4.36 |
| Heyman Richard A.Director | Jan 16, 2026 | Sell | 3,500 | $12.00 |
| Multani Pratik SOfficer — Chief Medical Officer | Dec 15, 2025 | Option exercise | 29,333 | $0.00 |
| Piscitelli DominicOfficer — Chief Financial Officer | Dec 15, 2025 | Option exercise | 29,333 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 21.9M | 15.4 | -0.3% |
| Apr 30, 2026 | 22.0M | 16.6 | +6.1% |
| Apr 15, 2026 | 20.7M | 5.7 | +7.2% |
| Mar 31, 2026 | 19.3M | 12.9 | -6.3% |
| Mar 13, 2026 | 20.7M | 12.0 | -5.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 4, 2026
- Other material eventMar 31, 2026
- Other material eventFeb 23, 2026
- Results of operationsFeb 23, 2026
- Other material eventDec 8, 2025
- Regulation FD disclosureNov 13, 2025
- Results of operationsNov 13, 2025
- Results of operations · Costs from exit or disposalAug 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13GMay 15, 2026
- SCHEDULE 13G/AMay 12, 2026
- 10-QMay 4, 2026
- 8-KMay 4, 2026
- ARSApr 28, 2026
- DEFA14AApr 28, 2026
- DEF 14AApr 28, 2026
- 8-KMar 31, 2026
- 4Feb 26, 2026
- 144Feb 24, 2026
- 8-KFeb 23, 2026
- 424B5Feb 23, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.